Log In
BCIQ
Print this Print this
 

Kynamro, mipomersen (ISIS 301012, ISIS 301012 subcutaneous)

  Manage Alerts
Collapse Summary General Information
Company Ionis Pharmaceuticals Inc.
DescriptionSecond-generation antisense inhibitor of Apolipoprotein B-100 (APOB-100) mRNA
Molecular Target Apolipoprotein B-100 (APOB-100) mRNA
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentApproved
Standard IndicationHypercholesterolemia
Indication DetailsTreat apheresis-eligible hypercholesterolemia patients; Treat familial hypercholesterolemia (FH); Treat heterozygous familial hypercholesterolemia (HeFH); Treat high-cholesterol patients at high risk for coronary heart disease; Treat high-risk hypercholesterolemia; Treat homozygous familial hypercholesterolemia (hoFH); Treat hypercholesterolemia; Treat severe high cholesterol; Treat severe hypercholesterolemia
Regulatory Designation U.S. - Orphan Drug (Treat homozygous familial hypercholesterolemia (hoFH));
U.S. - Standard Review (Treat homozygous familial hypercholesterolemia (hoFH))
PartnerKastle Therapeutics LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$95.0M

$25.0M

$70.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/03/2016

$95.0M

$25.0M

$70.0M

Get a free BioCentury trial today